(RTTNews) - Johnson & Johnson (JNJ), Thursday announced results from additional analyses of the Phase 2 DAHLIAS study, evaluating the effects of Nipocalimab in participants with primary Sjogren's ...
Zacks.com on MSN4h
Why Is Johnson & Johnson (JNJ) Down 6.7% Since Last Earnings Report?Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
"Latino male Trump voter told CNN mass deportation won't extend to law-abiding workers. 'That wouldn’t be fair. They need to ...
GET MORE AI-GENERATED SIGNALS: November 09, 2024, 09:42 am ET, BY Chris- Contributor| Editor: Thomas H. Kee Jr. ( Follow on ...
Shares of vaccine makers closed lower Thursday amid reports that President-elect Donald Trump was set to nominate vaccine ...
Johnson & Johnson has a high three-year median payout ratio of 71% (or a retention ratio of 29%), meaning that the company is ...
On Tuesday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $152.64 which represents a decrease of $-2.40 or -1.55% from the prior close of $155.04. The stock opened at $154.53 and ...
The first time Johnson & Johnson faced a lawsuit due to its talc-based baby powder causing cancer was way back in 1999. Since ...
Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...
Renaissance Technologies took new stakes in Micron Technology (NASDAQ:MU), Eli Lilly (NYSE:LLY), and Cisco Systems ...
Looking for the latest stock opportunities in December 2024? We have you covered. Click to read our top stock picks to ...
On Friday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $155.47 which represents a decrease of $-1.26 or -0.80% from the prior close of $156.73. The stock opened at $157 and touched ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback